Business Wire

New Real-World Data Support Long-Term Efficacy and Safety Profile of MAVENCLAD®

Share

Merck, a leading science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets), which further characterise the long-term efficacy and safety profile. These data are being shared at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place from 11–13 September, 2019, in Stockholm, Sweden.

“Our commitment to further understand the long-term efficacy and safety of MAVENCLAD goes beyond the safety profile seen in its clinical development programme, which includes up to 10 years of safety follow-up in some patients,” said Luciano Rossetti, Head of Global Research & Development for the biopharma business of Merck. “The data we are presenting at ECTRIMS 2019 exemplify this. They include key insights from real-world follow-up of patients from our clinical trials and the post-approval setting for MAVENCLAD, further validating it as an important treatment option available to patients in 69 countries worldwide.”

Results from a post hoc analysis (EP1573) evaluating five-year disease stability demonstrated sustained efficacy of cladribine tablets on disability progression, as measured by the Expanded Disability Status Scale (EDSS). According to study findings, 75% of patients showed stable or improved EDSS at five years post-treatment. The exploratory analysis was based on patients treated with cladribine tablets in CLARITY and then placebo in CLARITY Extension, with at least one post-baseline EDSS measurement.

Results were presented from a retrospective analysis (P617) of real-world follow-up data from an Italian multiple sclerosis (MS) registry, consisting of patients with clinically isolated syndrome or relapsing forms of MS who received at least one course of MAVENCLAD in the original clinical trial programme. At five years after receiving the last dose of MAVENCLAD, nearly two-thirds of patients (64%) had no disability progression and more than half of the patients (57%) were free of relapse.

“These data show us that MAVENCLAD continues to display sustained efficacy in a majority of patients at five years after starting treatment and that these results are consistent with data we are seeing from real-world experience,” said Prof. Gavin Giovannoni, a lead investigator in the CLARITY studies and Chair of Neurology, Barts and The London School of Medicine and Dentistry. “As a neurologist, this is important for me to see, as it shows that findings from the clinical development programme of MAVENCLAD will be borne out in clinical practice.”

In addition, final results (P1390) from the PREMIERE safety registry allowed for a thorough characterisation of the long-term safety profile of MAVENCLAD and showed no new safety findings. Furthermore, post-marketing data in the first 8,419 patients treated with MAVENCLAD worldwide were consistent with the safety profile seen in the MAVENCLAD clinical development programme, with no increase in incidence of adverse events from original clinical programme findings.

*About MAVENCLAD®
MAVENCLAD® is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD® for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® has since then been approved in 69 countries, including Canada, Australia and the U.S. Refer to the respective prescribing information for further details.

The clinical development programme for cladribine tablets includes:

  • The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients with RRMS.
  • The CLARITY extension study: a Phase III placebo-controlled study following on from the CLARITY study, which evaluated the safety and exploratory efficacy of cladribine tablets over two additional years beyond the two-year CLARITY study, according to the treatment assignment scheme for years 3 and 4.
  • The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).
  • The ONWARD (Oral Cladribine Added ON to Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.
  • PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis) study: a long-term observational follow-up safety registry of MS patients who participated in cladribine tablets clinical studies.

In the two-year CLARITY study, the most commonly reported adverse event (AE) in patients treated with cladribine tablets was lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators. Adverse Events reported in other clinical studies were similar.

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS, with a robust pipeline focusing on discovering new therapies that have the potential to modulate key pathogenic mechanisms in MS. Merck aims to improve the lives of those living with MS, by addressing areas of unmet medical needs.

The company’s robust immunology pipeline focuses on discovering new therapies that have the potential to modulate key pathogenic mechanisms in chronic diseases such as MS, systemic lupus erythematosus (SLE) and forms of arthritis, including rheumatoid arthritis (RA) and osteoarthritis (OA).

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Contact information

Tone Brauti Fritzen
tone-brauti.fritzen@merckgroup.com
+49 151 1454 2694

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alpega TMS Shows Impressive Triple-digit Growth in Expanding SME Segment17.2.2020 18:00:00 EETPress release

Alpega Group, the leading provider of cloud-based, end-to-end transportation and logistics management software in Europe, today announced that new business from its TMS software grew by 100% in the SME segment in 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005017/en/ Todd DeLaughter, Alpega Group CEO (Photo: Business Wire) Speaking on the results, Todd DeLaughter, Group CEO for Alpega said: “While the TMS market as a whole is growing in the high teens, we saw particular acceleration in the SME segment as more and more mid-size companies embrace technology to enable business efficiency and reduce cost while lowering carbon emissions. In 2019, we added 83 new clients for our TMS business.” “A big part of this success is down to the flexibility we offer our users. By bringing together the expertise of inet, Transwide and TenderEasy, Alpega TMS is able to cater to businesses dealing with all levels of logistics co

GSMA Board Statement on MWC Barcelona 202017.2.2020 18:00:00 EETPress release

The GSMA Board would like to express its sadness at the unavoidable cancellation of MWC Barcelona 2020. This decision is painful, but we believe the correct one. Health and safety are the priorities of all of the GSMA Board and Mobile Network Operators. Our sincere thoughts are with those affected in China and around the world in these trying times. Our vision at the GSMA is to unlock the power of connectivity so that people, industry and society thrive. MWC is crucial to convene and advance the industry and mobile ecosystem. The mobile industry is committed to harnessing the power of mobile technology and connectivity to transform the lives of billions of people around the world, and we are committed to a great MWC Barcelona 2021. The Board thanks GSMA management and the Host City Parties for their hard work throughout this challenging and unprecedented situation. We look forward to working together again for an even better MWC Barcelona 2021. The GSMA Board is comprised of 25 of the

Mary Kay Inc. Announces Actress, Philanthropist Monique Coleman as First-Ever Pink Changing Lives Honoree17.2.2020 17:00:00 EETPress release

Mary Kay Inc., a long-time leader in global female empowerment, is proud to announce Monique Coleman has been named the brand’s first-ever Pink Changing Lives Honoree. Pink Changing Lives—Mary Kay’s global commitment to celebrate the individuals and organizations that improve women’s and girls’ lives around the world—has supported more than three million women and their families by partnering with over 2,000 organizations and donating over $15 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005216/en/ Monique Coleman has been named Mary Kay Inc. first-ever Pink Changing Lives Honoree. (Photo: Mary Kay Inc.) Mary Kay’s Pink Changing Lives cause empowerment program donates funds to organizations focused on supporting cancer research, helping end hunger, protecting survivors from domestic abuse, beautifying communities, and many other programs empowering women and girls. In 2020, Mary Kay created the Pink Changing

ABS, the Royal Canadian Navy, and Defence Research & Development Canada Launch Digital Asset Framework Pilot17.2.2020 16:00:00 EETPress release

ABS today announced it is engaged in a pilot program with the Royal Canadian Navy (RCN) and Defence Research and Development Canada (DRDC) to deliver the ABS Digital Asset Framework for the RCN’s Maritime Coastal Defence Vessels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005014/en/ The HCMS Saskatoon (Photo: Business Wire) The ABS Digital Asset Framework forms the foundation of a broader Conditioned-Based Class program that transforms ship classification from a calendar-based schedule to a condition-based model. The project, which will start with HMCS Saskatoon, will support the RCN’s larger Digital Navy Initiative. “ABS is a leader in delivering condition-based maintenance data services in maritime and offshore applications, and we are proud that the RCN have chosen to work with us on this landmark project,” said Christopher J. Wiernicki, ABS Chairman, President and CEO. “Through our digital programs for commerci

Oasis Is Proud to Announce the Availability of HELIOS 5G, its Latest Release of Secure UICC Operating System17.2.2020 14:15:00 EETPress release

HELIOS 5G proposes enhanced security capabilities to secure critical communication services and respond actively to the greater range of possible threats associated with the wider variety of actors and devices types expected on the fifth generation of mobile network. Among many improvements implemented by Oasis R&D team, HELIOS 5G introduces new features to enable a device to authenticate to the 5G network with increased security and privacy of communications. The network authentication offered by Helios 5G is significantly stronger, due to longer crypto keys and an advanced algorithm. Additionally, the HELIOS OS benefits from a powerful onboard encryption including a SUCI calculator. It anonymizes the subscriber identity, thereby guaranteeing full subscriber privacy. Patrick Cao, Chief Operating Officer, said: “HELIOS 5G is an important milestone in the development history of our Helios SIM and eSIM Operating System. It demonstrates the expertise of our R&D team and confirms our posit

1.86 Customer Minutes Lost (CML) of Electricity per Year in Dubai17.2.2020 13:08:00 EETPress release

Dubai Electricity and Water Authority (DEWA) has achieved a new world record in electricity Customer Minutes Lost (CML) per year. DEWA recorded 1.86 minutes, in Dubai, compared to around 15 minutes recorded by leading electricity companies in the European Union. This is a new addition to DEWA’s record of international achievements in electricity and water services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005093/en/ Dubai Electricity and Water Authority (DEWA) achieves a new world record in electricity Customer Minutes Lost (CML) per year and enhances Dubai’s prosperity. (Photo : AETOSWire). “At DEWA, we work according to the vision and directives of our leadership to provide a robust infrastructure according to the highest international standards. We continuously work to enhance the capacity and efficiency of transmission and distribution networks to provide electricity and water services according to the highes

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom